NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

That doesn't say what you say elsewhere it says it says. This is more of the same false information. You pointed and quoted something that has nothing to do with what you said previously and what I called you out on, and you did it as if you were proving me wrong. You need to go back and figure out what you're actually trying to say here. No one is questioning the crossover. We all know that happened.

There is no issue about "single dose" or "double dose". Your previous post was deeply confused. Your answer is not on point.

This is what I called you out on:

The DCVax-L treatment arm used a crossover dosing when patients were diagnosed as recurring GBM (progression). 90% of the treatment arm had crossover (2nd dose) during the trial. That is the double dosing. It is in the SAP document.

The external comparator trials were not screened for dosing and most were single dosed. Thus DCVax-L had two doses, most comparator trials used single dose. That is confounding the trial results. NWBO statisticians statistically manipulated the OS endpoint data to try to compensate for the confounding of the data. That was their attempt to make it acceptable for regulators. FDA not likely to buy it.